GeoVax Labs (GOVX) vs China SXT Pharmaceuticals (SXTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
GeoVax Labs is the larger company by market cap ($985,459 vs $273,955), about 3.6 times the size, while China SXT Pharmaceuticals is growing revenue faster (-34.6% vs -37.1%). China SXT Pharmaceuticals converts more of its revenue into profit, with a net margin of -545.2% versus -862.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GOVX | SXTC |
|---|---|---|
| Share price | $1.81 | $2.65 |
| Market cap | $985.46K | $273.95K |
| 1-day change | -5.24% | +2.12% |
| EPS (TTM) | $-15.03 | $-73,040.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.49M | $1.14M |
| Revenue growth (YoY) | -37.06% | -34.63% |
| Net income (latest FY) | $-21.46M | $-6.21M |
| Gross margin | — | 21.85% |
| Operating margin | -869.34% | -625.89% |
| Net margin | -862.34% | -545.24% |
| 52-week high | $270.60 | $8,376,000.00 |
| 52-week low | $1.51 | $2.52 |
| Distance from 52-week high | -99.33% | -100.00% |
| Analyst consensus | none | — |
| Avg. price target upside | +452.49% | — |
| Average volume | 213.41K | 234.25K |
| Shares outstanding | 544.45K | 103.58K |
| Employees | 19 | 56 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GeoVax Labs is about 3.6 times larger than China SXT Pharmaceuticals by market value ($985.46K vs $273.95K).
- China SXT Pharmaceuticals is more profitable, keeping -545.2 cents of every revenue dollar as net income versus -862.3 cents for GeoVax Labs.
About GeoVax Labs
GOVX stock →GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About China SXT Pharmaceuticals
SXTC stock →China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
GOVX vs SXTC FAQ
Which is bigger, GeoVax Labs or China SXT Pharmaceuticals?
GeoVax Labs (GOVX) is larger, with a market capitalization of $985.46K compared with $273.95K for China SXT Pharmaceuticals (SXTC).
Are GeoVax Labs and China SXT Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.